Wuxi Biologics (Cayman) Inc. KKPS DR (WUXI06) – aksjekurser og nyheter

WUXI06:BKK

Wuxi Biologics (Cayman) Inc. KKPS DR

5,20 THB

0,00%

(0,00) 1 D

15. okt., 16:40:00 GMT+7 · THB

Alle symboler

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for WUXI06 …

Åpne

5,25 THB

Høy

5,35 THB

Lav

5,05 THB

Markedsverdi

200,24 mrd.

Snittvolum

93,60k

Volum

288,50k

52 u høy

6,25 THB

52 u lav

3,02 THB

Utestående aksjer

4,12 mrd.

Antall ansatte

15k

Åpne

5,25 THB

Høy

5,35 THB

Lav

5,05 THB

Markedsverdi

200,24 mrd.

Snittvolum

93,60k

Volum

288,50k

52 u høy

6,25 THB

52 u lav

3,02 THB

Utestående aksjer

4,12 mrd.

Antall ansatte

15k

Relaterte aksjer

AIA06

Aia Group Limited KKPS DR

3,12 THB

−0,64%

ICBC06

Industrial and Commercial Bank of China

Nyhetssaker

Fra nettkilder og nyhetspartnere

Vietnam.vn

for 22 timer siden

Hurtiglesning 15-10: S&P 500 opplever det største fallet siden juli etter inflasjonsdata, PV GAS' 9-månedersresultat nesten dobler årsmålet.

Investor's Business Daily

for 17 minutter siden

Futures Fall After Wild Day; Tesla Roadster On Tap

Yahoo Finance

for 1 time siden

Grayscale Says Bitcoin’s Volatility Falls to 43%, Now Within S&P 500 Range

Moomoo

for 1 time siden

Dow Jones Top Company Headlines at 7 PM ET: Netflix Replaces Content Chief as It Struggles to Engage Viewers | Tesla's ...

Profil

WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia

Om Wuxi Biologics (Cayman) Inc. KKPS DR

Administrerende direktørZhisheng Chen

Ansatte14,7k

Grunnlagt2010

Hovedkontor-

Sektor-

Nettstedwuxibiologics.com

Alle verdier i CNY	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	5,92 mrd.	5,92 mrd.	5,89 mrd.	5,89 mrd.
Varekostnad	3,04 mrd.	3,04 mrd.	3,17 mrd.	3,17 mrd.
Direkte driftskostnader	3,04 mrd.	3,04 mrd.	3,17 mrd.	3,17 mrd.
Utgifter til forskning og utvikling	254,93 mill.	254,93 mill.	215,11 mill.	215,11 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	631,03 mill.	631,03 mill.	591,61 mill.	591,61 mill.
Driftskostnader	921,71 mill.	921,71 mill.	860,09 mill.	860,09 mill.
Totale driftskostnader	3,96 mrd.	3,96 mrd.	4,03 mrd.	4,03 mrd.
Driftsinntekter	1,96 mrd.	1,96 mrd.	1,86 mrd.	1,86 mrd.
Andre ikke-operasjonelle inntekter	33,58 mill.	33,58 mill.	42,20 mill.	42,20 mill.
EBT inkludert uvanlige elementer	1,96 mrd.	1,96 mrd.	1,71 mrd.	1,71 mrd.
EBT uten uvanlige elementer	1,94 mrd.	1,94 mrd.	1,70 mrd.	1,70 mrd.
Kostnad for inntektsskatt	476,10 mill.	476,10 mill.	251,54 mill.	251,54 mill.
Faktisk avgiftssats	24,24 %	24,24 %	14,71 %	14,71 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	1,28 mrd.	1,28 mrd.	1,22 mrd.	1,22 mrd.
Netto fortjenestemargin	21,70 %	21,70 %	20,70 %	20,70 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	115,29 mill.	115,29 mill.	106,38 mill.	106,38 mill.
Rentekostnader	−29,76 mill.	−29,76 mill.	−22,28 mill.	−22,28 mill.
Netto rentekostnader	85,53 mill.	85,53 mill.	84,10 mill.	84,10 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	2,24 mrd.	2,24 mrd.	2,27 mrd.	2,27 mrd.
Gevinst eller tap ved salg av eiendeler	317,34 mill.	317,34 mill.	-	-

Spør om hva som helst